HIV- und AIDS-Forschungsjournal

A Review on Novel Antiretroviral Drug Therapy Approved by FDA Since 2019

Niralee B Patel* and Ruchita J Patel

Currently 33 anti-HIV compounds have been formally approved for clinical use in the treatment of HIV/AIDS. These compounds divided into eight different categories: Nucleoside reverse transcriptase inhibitors or Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FIs), post attachment inhibitors, co-receptor (CCR5/CXCR4) inhibitor, Integrase Inhibitors (INIs) and pharmacokinetic enhancer. They are targeting critical steps involve in HIV replication including viral entry, fusion, reverse transcription and integration process. These compounds are also used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development. In this review we will summarized the basic fact about HIV/AIDS, life cycle of HIV virus in various stages, target with drug class and also include recently approved drugs and their combination therapy by FDA.